Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired XXXX : a retrospective analysis.

@entity1 @entity281 @entity2150 @entity1641
UNASSIGNED: Studies comparing rabbit antithymocyte globulin (rATG) and @entity1641 ATG (hATG) in @entity1 with @entity2150 ( @entity2150 ) have shown conflicting results. These studies included fewer than 60 subjects in the rATG arm with relatively short follow-up. A total of 169 @entity1 treated with rATG and 62 treated with hATG were included in this retrospective analysis, across 33 centers. @entity1 were treated with rATG or hATG plus cyclosporine A. Over half were classified, as having severe @entity2150 (SAA) or very severe @entity2150 (VSAA), and the mean follow-up was 45  months. There was no significant difference detected in cumulative response to treatment or survival between the rATG and hATG groups. The response to treatment was 63  % in the rATG group versus 66  % in the hATG group at 3  months. By 12  months, this pattern had reversed, and 84  % of rATG @entity1 had responded to treatment versus 76  % in the hATG group (n.s.). Early mortality due to @entity281 tended to be higher with rATG compared to hATG (n.s). rATG and hATG would seem to be therapeutically equivalent in SAA and VSAA. However, @entity1 treated with rATG may take longer to respond than those treated with hATG and may also require more active prevention of @entity281 .
